Search for: All records

Abstract Magnetic liquid metal (MLM) is a mixture of magnetic particles with gallium‐based liquid metals which utilizes an unconventional combination of fluidity, high thermal/electrical conductivity, biocompatibility, and magnetism. Recently, from materials to applications, studies on MLMs have drastically increased. Single or multiple MLMs can be precisely positioned or can act as a carrier for handling other objects. MLMs are also used in biomedical applications such as cancer treatment by hyperthermia and precision delivery of cancer drugs on tumors, or antibacterial coating which kills bacteria. In electronics applications, MLMs are used for magnetic field‐driven patterning of metallic lines, reconfigurable interconnects, electronic tattoos, and reconfigurable electromagnetic wave shielding. Phase change (solid/liquid) of MLMs adds another unique capability, morphing. A combination of innovations in the micro/nano robots and MLMs has huge potential to bring an unprecedented disruptive technology for a wide variety of applications including self‐morphing shape‐recovery robots, highly localized cancer treatment, and reconfigurable stealth/camouflage, among others. This article comprehensively reviews recent developments in MLMs from the materials to methods of preparation, locomotion of MLMs, their applications, and future outlooks. 

Intestinal barrier dysfunction, which leads to translocation of bacteria or toxic bacterial products from the gut into bloodstream and results in systemic inflammation, is a key pathogenic factor in many human diseases. However, the molecular mechanisms leading to intestinal barrier defects are not well understood, and there are currently no available therapeutic approaches to target intestinal barrier function. Here we show that soluble epoxide hydrolase (sEH) is an endogenous regulator of obesity-induced intestinal barrier dysfunction. We find that sEH is overexpressed in the colons of obese mice. In addition, pharmacologic inhibition or genetic ablation of sEH abolishes obesity-induced gut leakage, translocation of endotoxin lipopolysaccharide or bacteria, and bacterial invasion-induced adipose inflammation. Furthermore, systematic treatment with sEH-produced lipid metabolites, dihydroxyeicosatrienoic acids, induces bacterial translocation and colonic inflammation in mice. The actions of sEH are mediated by gut bacteria-dependent mechanisms, since inhibition or genetic ablation of sEH fails to attenuate obesity-induced gut leakage and adipose inflammation in mice lacking gut bacteria. Overall, these results support that sEH is a potential therapeutic target for obesity-induced intestinal barrier dysfunction, and that sEH inhibitors, which have been evaluated in human clinical trials targeting other human disorders, could be promising agents for prevention and/or treatment.